vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $123.8M, roughly 1.6× NATURES SUNSHINE PRODUCTS INC). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs 2.2%, a 1.1% gap on every dollar of revenue. On growth, ROGERS CORP posted the faster year-over-year revenue change (5.2% vs 4.7%). NATURES SUNSHINE PRODUCTS INC produced more free cash flow last quarter ($7.6M vs $1.1M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -3.3%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
NATR vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $200.5M |
| Net Profit | $4.1M | $4.5M |
| Gross Margin | 72.5% | 32.2% |
| Operating Margin | 4.3% | — |
| Net Margin | 3.3% | 2.2% |
| Revenue YoY | 4.7% | 5.2% |
| Net Profit YoY | 1379.4% | 421.4% |
| EPS (diluted) | $0.23 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $123.8M | $201.5M | ||
| Q3 25 | $128.3M | $216.0M | ||
| Q2 25 | $114.8M | $202.8M | ||
| Q1 25 | $113.2M | $190.5M | ||
| Q4 24 | $118.2M | $192.2M | ||
| Q3 24 | $114.6M | $210.3M | ||
| Q2 24 | $110.6M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $4.1M | $4.6M | ||
| Q3 25 | $5.3M | $8.6M | ||
| Q2 25 | $5.3M | $-73.6M | ||
| Q1 25 | $4.7M | $-1.4M | ||
| Q4 24 | $-321.0K | $-500.0K | ||
| Q3 24 | $4.3M | $10.7M | ||
| Q2 24 | $1.3M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 72.5% | 31.5% | ||
| Q3 25 | 73.3% | 33.5% | ||
| Q2 25 | 71.7% | 31.6% | ||
| Q1 25 | 72.1% | 29.9% | ||
| Q4 24 | 72.0% | 32.1% | ||
| Q3 24 | 71.3% | 35.2% | ||
| Q2 24 | 71.4% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 4.3% | 3.5% | ||
| Q3 25 | 7.0% | 7.3% | ||
| Q2 25 | 3.7% | -33.3% | ||
| Q1 25 | 5.4% | -0.2% | ||
| Q4 24 | 3.8% | -6.6% | ||
| Q3 24 | 4.6% | 6.9% | ||
| Q2 24 | 5.1% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 3.3% | 2.3% | ||
| Q3 25 | 4.2% | 4.0% | ||
| Q2 25 | 4.6% | -36.3% | ||
| Q1 25 | 4.2% | -0.7% | ||
| Q4 24 | -0.3% | -0.3% | ||
| Q3 24 | 3.8% | 5.1% | ||
| Q2 24 | 1.2% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.23 | $0.20 | ||
| Q3 25 | $0.30 | $0.48 | ||
| Q2 25 | $0.28 | $-4.00 | ||
| Q1 25 | $0.25 | $-0.08 | ||
| Q4 24 | $-0.02 | $-0.04 | ||
| Q3 24 | $0.23 | $0.58 | ||
| Q2 24 | $0.07 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $161.6M | $1.2B |
| Total Assets | $261.1M | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $93.9M | $197.0M | ||
| Q3 25 | $95.6M | $167.8M | ||
| Q2 25 | $81.3M | $157.2M | ||
| Q1 25 | $86.5M | $175.6M | ||
| Q4 24 | $84.7M | $159.8M | ||
| Q3 24 | $78.7M | $146.4M | ||
| Q2 24 | $68.7M | $119.9M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $161.6M | $1.2B | ||
| Q3 25 | $166.7M | $1.2B | ||
| Q2 25 | $163.7M | $1.2B | ||
| Q1 25 | $167.1M | $1.3B | ||
| Q4 24 | $161.0M | $1.3B | ||
| Q3 24 | $162.6M | $1.3B | ||
| Q2 24 | $156.4M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $261.1M | $1.4B | ||
| Q3 25 | $264.8M | $1.4B | ||
| Q2 25 | $254.9M | $1.5B | ||
| Q1 25 | $252.7M | $1.5B | ||
| Q4 24 | $240.9M | $1.5B | ||
| Q3 24 | $245.3M | $1.5B | ||
| Q2 24 | $235.8M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $5.8M |
| Free Cash FlowOCF − Capex | $7.6M | $1.1M |
| FCF MarginFCF / Revenue | 6.1% | 0.5% |
| Capex IntensityCapex / Revenue | 1.9% | 2.3% |
| Cash ConversionOCF / Net Profit | 2.41× | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $9.9M | $46.9M | ||
| Q3 25 | $18.5M | $28.9M | ||
| Q2 25 | $4.3M | $13.7M | ||
| Q1 25 | $2.6M | $11.7M | ||
| Q4 24 | $12.2M | $33.7M | ||
| Q3 24 | $9.6M | $42.4M | ||
| Q2 24 | $1.3M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $7.6M | $42.2M | ||
| Q3 25 | $16.8M | $21.2M | ||
| Q2 25 | $3.0M | $5.6M | ||
| Q1 25 | $1.5M | $2.1M | ||
| Q4 24 | $10.0M | $18.3M | ||
| Q3 24 | $7.9M | $25.2M | ||
| Q2 24 | $-2.0M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 6.1% | 20.9% | ||
| Q3 25 | 13.1% | 9.8% | ||
| Q2 25 | 2.6% | 2.8% | ||
| Q1 25 | 1.3% | 1.1% | ||
| Q4 24 | 8.5% | 9.5% | ||
| Q3 24 | 6.9% | 12.0% | ||
| Q2 24 | -1.9% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.9% | 2.3% | ||
| Q3 25 | 1.3% | 3.6% | ||
| Q2 25 | 1.2% | 4.0% | ||
| Q1 25 | 1.0% | 5.0% | ||
| Q4 24 | 1.9% | 8.0% | ||
| Q3 24 | 1.5% | 8.2% | ||
| Q2 24 | 3.0% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 2.41× | 10.20× | ||
| Q3 25 | 3.46× | 3.36× | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | 3.96× | ||
| Q2 24 | 0.97× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
ROG
Segment breakdown not available.
